The healthcare community is abuzz about the new drug, a dual-action treatment showing remarkable outcomes in preliminary studies . This groundbreaking compound, a glucagon-like peptide-1 receptor agonist alongside a glucose-dependent insulinotropic molecule , appears to effectively decrease body weight and improve metabolic function . Researchers a